Search

Your search keyword '"Kaye, David M."' showing total 1,529 results
Start Over Author "Kaye, David M."
1,529 results on '"Kaye, David M."'

8. Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials

Author

Litwin, Sheldon E., Komtebedde, Jan, Borlaug, Barry A., Kaye, David M., Hasenfuβ, Gerd, Kawash, Rami, Hoendermis, Elke, Hummel, Scott L., Cikes, Maja, Gustafsson, Finn, Chung, Eugene S., Mohan, Rajeev C., Sverdlov, Aaron L., Swarup, Vijendra, Winkler, Sebastian, Hayward, Christopher S., Bergmann, Martin W., Bugger, Heiko, McKenzie, Scott, Nair, Ajith, Rieth, Andreas, Burkhoff, Daniel, Cutlip, Donald E., Solomon, Scott D., van Veldhuisen, Dirk J., Leon, Martin B., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

10. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

Author

Gustafsson, Finn, Petrie, Mark C., Komtebedde, Jan, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G.F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Solomon, Scott D., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

16. Hypothermic oxygenated perfusion (HOPE) safely and effectively extends acceptable donor heart preservation times: Results of the Australian and New Zealand trial

Author

McGiffin, David C., Kure, Christina E., Macdonald, Peter S., Jansz, Paul C., Emmanuel, Sam, Marasco, Silvana F., Doi, Atsuo, Merry, Chris, Larbalestier, Robert, Shah, Amit, Geldenhuys, Agneta, Sibal, Amul K., Wasywich, Cara A., Mathew, Jacob, Paul, Eldho, Cheshire, Caitlin, Leet, Angeline, Hare, James L., Graham, Sandra, Fraser, John F., and Kaye, David M.

Published
2024
Full Text
View/download PDF

22. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction

Author

Litwin, Sheldon E., Komtebedde, Jan, Hu, Mo, Burkhoff, Daniel, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Gorter, Thomas M., Demers, Catherine, Shetty, Ranjith, Lewis, Gregory, Starling, Randall C., Patel, Sanjay, Gupta, Deepak K., Morsli, Hakim, Penicka, Martin, Cikes, Maja, Gustafsson, Finn, Silvestry, Frank E., Rowin, Ethan J., Cutlip, Donald E., Leon, Martin B., Kitzman, Dalane W., Kleber, Franz X., and Shah, Sanjiv J.

Published
2023
Full Text
View/download PDF

24. Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial

Author

Chieng, David, Sugumar, Hariharan, Segan, Louise, Tan, Caleb, Vizi, Donna, Nanayakkara, Shane, Al-Kaisey, Ahmed, Hawson, Joshua, Prabhu, Sandeep, Voskoboinik, Aleksandr, Finch, Sue, Morton, Joseph B., Lee, Geoffrey, Mariani, Justin, La Gerche, Andre, Taylor, Andrew J., Howden, Erin, Kistler, Peter M., Kalman, Jonathan M., Kaye, David M., and Ling, Liang-Han

Published
2023
Full Text
View/download PDF

36. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

37. Fulminant eosinophilic myocarditis and refractory ventricular arrhythmias requiring mechanical circulatory support: a case report.

Author

Brick, Claudia, Leet, Angeline, Tay, Hui, Kaye, David M, and Taylor, Andrew J

Subjects
HYPEREOSINOPHILIC syndrome, VENTRICULAR arrhythmia, ARTIFICIAL blood circulation, HEART failure, CARDIAC magnetic resonance imaging, VENTRICULAR fibrillation, MYOCARDITIS
Abstract

Background Fulminant eosinophilic myocarditis (EM) is a rare and often fatal condition that may present atypically and be complicated by ventricular arrhythmias. Treatment involves high-dose corticosteroids to suppress eosinophilia, as well as increasing use of mepolizumab, an anti-interleukin-5 antibody with evidence for long-term efficacy and safety. Case summary A 38-year-old woman presented to the emergency department with neck pain and fatigue, and after extensive investigation was diagnosed with EM secondary to idiopathic hypereosinophilic syndrome. The patient was treated with methylprednisolone for eosinophil suppression and warfarin due to the presence of biventricular apical thrombi. Despite previously stable haemodynamics, the patient had a cardiac arrest due to ventricular fibrillation on Day 11 of hospitalization, requiring 30 min of cardiopulmonary resuscitation and commencement of veno-arterial extracorporeal membrane oxygenation support due to refractory ventricular arrhythmias. The patient was urgently listed for heart transplant but a suitable match was not identified, and she was weaned to pharmacologic support on Day 34. The patient survived with minimal sequelae and has returned to full-time work. She remains on mepolizumab as a steroid-sparing agent, therapeutic anti-coagulation, and heart failure therapy. Discussion This report describes an atypical presentation of fulminant EM requiring weeks of mechanical circulatory support due to refractory arrhythmia rather than heart failure. The case also highlighted the benefits of non-invasive cardiac magnetic resonance imaging in both diagnosis and prognostication of EM, as well as the need to maintain a high index of suspicion for this rare disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction.

Author

Nan Tie, Emilia, Wolsk, Emil, Nanayakkara, Shane, Vizi, Donna, Mariani, Justin, Moller, Jacob Eifer, Hassager, Christian, Gustafsson, Finn, and Kaye, David M.

Subjects
BLOOD lactate, AEROBIC capacity, CHRONIC kidney failure, HEART failure, CARDIAC catheterization
Abstract

Aims: Heart failure with preserved ejection fraction (HFpEF) is associated with an array of central and peripheral haemodynamic and metabolic changes. The exact pathogenesis of exercise limitation in HFpEF remains uncertain. Our aim was to compare lactate accumulation and central haemodynamic responses to exercise in patients with HFpEF, non‐cardiac dyspnoea (NCD), and healthy volunteers. Methods and results: Right heart catheterization with mixed venous blood gas and lactate measurements was performed at rest and during symptom‐limited supine exercise. Multivariable analyses were conducted to determine the relationship between haemodynamic and biochemical parameters and their association with exercise capacity. Of 362 subjects, 198 (55%) had HFpEF, 103 (28%) had NCD, and 61 (17%) were healthy volunteers. This included 139 (70%) females with HFpEF, 77 (75%) in NCD (P = 0.41 HFpEF vs. NCD), and 31 (51%) in healthy volunteers (P < 0.001 HFpEF vs. volunteers). The median age was 71 (65, 75) years in HFpEF, 66 (57, 72) years in NCD, and 49 (38, 65) years in healthy volunteers (HFpEF vs. NCD or volunteer, both P < 0.001). Peak workload was lower in HFpEF compared with healthy volunteers [52 W (interquartile range 31–73), 150 W (125–175), P < 0.001], but not NCD [53 W (33, 75), P = 0.85]. Exercise lactate indexed to workload was higher in HFpEF at 0.08 mmol/L/W (0.05–0.11), 0.06 mmol/L/W (0.05–0.08; P = 0.016) in NCD, and 0.04 mmol/L/W (0.03–0.05; P < 0.001) in volunteers. Exercise cardiac index was 4.5 L/min/m2 (3.7–5.5) in HFpEF, 5.2 L/min/m2 (4.3–6.2; P < 0.001) in NCD, and 9.1 L/min/m2 (8.0–9.9; P < 0.001) in volunteers. Oxygen delivery in HFpEF was lower at 1553 mL/min (1175–1986) vs. 1758 mL/min (1361–2282; P = 0.024) in NCD and 3117 mL/min (2667–3502; P < 0.001) in the volunteer group during exercise. Predictors of higher exercise lactate levels in HFpEF following adjustment included female sex and chronic kidney disease (both P < 0.001). Conclusions: HFpEF is associated with reduced exercise capacity secondary to both central and peripheral factors that alter oxygen utilization. This results in hyperlactataemia. In HFpEF, plasma lactate responses to exercise may be a marker of haemodynamic and cardiometabolic derangements and represent an important target for future potential therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Influence of angiotensin II on the gut microbiome: modest effects in comparison to experimental factors.

Author

Muralitharan, Rikeish R, Nakai, Michael E, Snelson, Matthew, Zheng, Tenghao, Dinakis, Evany, Xie, Liang, Jama, Hamdi, Paterson, Madeleine, Shihata, Waled, Wassef, Flavia, Vinh, Antony, Drummond, Grant R, Kaye, David M, Mackay, Charles R, and Marques, Francine Z

Subjects
ANGIOTENSIN II, GUT microbiome, SHORT-chain fatty acids, MICROBIAL metabolites, LABORATORY mice
Abstract

Aims Animal models are regularly used to test the role of the gut microbiome in hypertension. Small-scale pre-clinical studies have investigated changes to the gut microbiome in the angiotensin II hypertensive model. However, the gut microbiome is influenced by internal and external experimental factors, which are not regularly considered in the study design. Once these factors are accounted for, it is unclear if microbiome signatures are reproduceable. We aimed to determine the influence of angiotensin II treatment on the gut microbiome using a large and diverse cohort of mice and to quantify the magnitude by which other factors contribute to microbiome variations. Methods and results We conducted a retrospective study to establish a diverse mouse cohort resembling large human studies. We sequenced the V4 region of the 16S rRNA gene from 538 samples across the gastrointestinal tract of 303 male and female C57BL/6J mice randomized into sham or angiotensin II treatment from different genotypes, diets, animal facilities, and age groups. Analysing over 17 million sequencing reads, we observed that angiotensin II treatment influenced α-diversity (P = 0.0137) and β-diversity (i.e. composition of the microbiome, P < 0.001). Bacterial abundance analysis revealed patterns consistent with a reduction in short-chain fatty acid producers, microbial metabolites that lower blood pressure. Furthermore, animal facility, genotype, diet, age, sex, intestinal sampling site, and sequencing batch had significant effects on both α- and β-diversity (all P < 0.001). Sampling site (6.8%) and diet (6%) had the largest impact on the microbiome, while angiotensin II and sex had the smallest effect (each 0.4%). Conclusion Our large-scale data confirmed findings from small-scale studies that angiotensin II impacted the gut microbiome. However, this effect was modest relative to most of the other factors studied. Accounting for these factors in future pre-clinical hypertensive studies will increase the likelihood that microbiome findings are replicable and translatable. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction

Author

Wang, Yu-Chen, primary, Koay, Yen Chin, additional, Pan, Calvin, additional, Zhou, Zhiqiang, additional, Wilson Tang, W.H., additional, Wilcox, Jennifer, additional, Li, Xinmin S., additional, Zagouras, Alexia, additional, Marques, Francine, additional, Allayee, Hooman, additional, Rey, Federico E., additional, Kaye, David M., additional, O’Sullivan, John F., additional, Hazen, Stanley L., additional, Cao, Yang, additional, and Lusis, Aldons J., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results